West Pharmaceutical Services (WST) Net Income towards Common Stockholders (2009 - 2026)

West Pharmaceutical Services has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $135.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $135.4 million, up 56.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $528.3 million (up 16.52% YoY), and the FY2025 annual result was $479.3 million, changed 0.27% from the prior year.
• Net Income towards Common Stockholders came in at $135.4 million for Q1 2026 at West Pharmaceutical Services, up from $128.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $183.0 million in Q2 2022 to a low of $86.4 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is $132.1 million (2024), against an average of $131.4 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 32.43% in 2022 and jumped 56.71% in 2026, its largest moves.
• West Pharmaceutical Services' Net Income towards Common Stockholders stood at $99.8 million in 2022, then jumped by 33.97% to $133.7 million in 2023, then slipped by 4.19% to $128.1 million in 2024, then grew by 0.08% to $128.2 million in 2025, then increased by 5.62% to $135.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $135.4 million (Q1 2026), $128.2 million (Q4 2025), and $137.9 million (Q3 2025), per Business Quant data.